TMED10抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-6: NIH/3T3 cell, Mouse Pancreas tissue, Rat lung tissue, Mouse liver tissue, Hela, Raji cell lysates, Primary antibody: P10314(TMED10 Antibody) at dilution 1/900, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P10314(TMED10 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10314(TMED10 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

TMED10 (Transmembrane emp24 domain-containing protein 10), also known as p24a or TMP21. is a member of the transmembrane emp24 domain-containing protein family. It is primarily localized in the Golgi apparatus and endoplasmic reticulum, playing a critical role in vesicular trafficking, protein sorting, and secretion. TMED10 is involved in the formation of transport vesicles and interacts with components of the COPI and COPII complexes, facilitating cargo selection and membrane protein packaging. Additionally, it has been implicated in regulating γ-secretase activity, influencing amyloid-beta (Aβ) production in Alzheimer’s disease research.

TMED10 antibodies are essential tools for studying its expression, localization, and function in cellular processes. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate TMED10's role in protein trafficking, secretory pathways, and disease mechanisms. Polyclonal and monoclonal antibodies targeting specific epitopes of TMED10 are commercially available, often validated for specificity in human, mouse, or rat models. Recent studies also explore TMED10's involvement in cancer progression, immune responses, and neurodegenerative disorders, highlighting its therapeutic potential. Researchers rely on these antibodies to dissect molecular pathways and validate TMED10 as a biomarker or drug target.